MADRID, 3 Oct. (CNMV) -
Almirall to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis
Información completa en:
http://www.cnmv.es/portal/hr/HRAlDia.aspx?lang=es .
